留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

围手术期无抗凝体外膜肺氧合辅助肺移植治疗8例分析

杨冰心 李敏 周蓉 马千里 杜忠军 詹庆元

杨冰心, 李敏, 周蓉, 等. 围手术期无抗凝体外膜肺氧合辅助肺移植治疗8例分析[J]. 器官移植, 2018, 9(2): 152-155. doi: 10.3969/j.issn.1674-7445.2018.02.011
引用本文: 杨冰心, 李敏, 周蓉, 等. 围手术期无抗凝体外膜肺氧合辅助肺移植治疗8例分析[J]. 器官移植, 2018, 9(2): 152-155. doi: 10.3969/j.issn.1674-7445.2018.02.011

围手术期无抗凝体外膜肺氧合辅助肺移植治疗8例分析

doi: 10.3969/j.issn.1674-7445.2018.02.011
详细信息
    作者简介:

    杨冰心,女,1982年生,硕士,主治医师,研究方向为重症医学,Email: bingxin1230yang@sohu.com

    通讯作者:

    李敏,男,1982年生,硕士,主治医师,研究方向为呼吸危重症,Email: qlyy_limin@163.com

  • 中图分类号: R617, R563

  • 摘要:   目的  探讨无抗凝体外膜肺氧合(ECMO)在肺移植围手术期中应用的可行性。  方法  回顾性分析2017年5月至7月在中日友好医院接受围手术期无抗凝ECMO辅助治疗的8例肺移植患者临床资料。其中男6例,女2例,年龄(52±12)岁。所使用的ECMO套包管路为肝素涂层管路,监测患者肺移植术后应用无抗凝ECMO时间,记录患者停用无抗凝ECMO后吸入氧浓度(FiO2)、24 h及48 h动脉血氧分压(PaO2)/FiO2,观察患者术后并发症发生情况。  结果  8例患者应用无抗凝ECMO的时间中位数为48(34~53)h,停用无抗凝ECMO后FiO2为27%~30%;停用无抗凝ECMO后24 h PaO2/FiO2为(314±54)mmHg,48 h PaO2/FiO2为(306±24)mmHg(10 mmHg=1.33 kPa)。8例患者围手术期无抗凝ECMO辅助治疗的肺移植患者均成功撤离ECMO,ECMO运转过程及停用无抗凝ECMO后均未发生膜肺血栓及无抗凝ECMO相关血栓性疾病。  结论  对有出血倾向的患者,肺移植围手术期应用有肝素涂层管路的ECMO套包进行无抗凝ECMO是安全、可行的。

     

  • [1] HARDY JD, WEBB WR, DALTON ML JR, et a1. Lung homotransplantaion in man[J]. JAMA, 1963, 186: 1065-1074. https://www.ncbi.nlm.nih.gov/pubmed/14061414
    [2] YUSEN RD, EDWARDS LB, KUCHERYAVAYA AY, et al. The registry of the international society for heart and lung transplantation: thirty-second official adult lung and heart-lung transplantation report-2015; focus theme: early graft failure[J]. J Heart Lung Transplant, 2015, 34(10): 1264-1277. DOI: 10.1016/j.healun.2015.08.014.
    [3] 毛文君, 陈静瑜. 中国肺移植面临的困难及对策[J/CD]. 中华胸部外科电子杂志, 2016, 3(1): 1-6. DOI: 10.3877/cma.j.issn.2095-8773.2016.01.001.

    MAO WJ, CHEN JY. Difficulties and countermeasures of lung transplantation in China[J/CD]. Chin J Thorac Surg (Electr Vers), 2016, 3(1): 1-6. DOI: 10.3877/cma.j.issn.2095-8773.2016.01.001.
    [4] COTTINI SR, WENGER U, SAILER S, et al. Extracorporeal membrane oxygenation: beneficial strategy for lung transplant recipients[J]. J Extra Corpor Technol, 2013, 45(1): 16-20.
    [5] 王凯. 体外膜肺氧合在肺移植围术期的应用进展[J/CD]. 实用器官移植电子杂志, 2016, 4(3): 190-192. DOI: 10.3969/j.issn.2095-5332.2016.03.016.

    WANG K. The application of extracorporeal lung oxygenation in the perioperative period of lung transplantation[J/CD]. Pract J Organ Transplant (Electr Vers), 2016, 4(3): 190-192. DOI: 10.3969/j.issn.2095-5332.2016.03.016.
    [6] BRODT J, GOLOGORSKY D, WALTER S, et al. Orbital compartment syndrome following extracorporeal support[J]. J Card Surg, 2013, 28(5): 522-524. DOI: 10.1111/Jocs.12196.
    [7] ESPOSITO AJ, BHATRAJU PK, STAPLETON RD, et al. Hyaluronic acid is associated with organ dysfunction in acute respiratory distress syndrome[J]. Crit Care, 2017, 21(1): 304. DOI: 10.1186/s13054-017-1895-7.
    [8] MAL H, DEHOUX M, SLEIMAN C, et al. Early release of proinflammatory cytokines after lung transplantation[J]. Chest, 1998, 113(3): 645-651. doi: 10.1378/chest.113.3.645
    [9] CYPEL M, KESHAVJEE S. Extracorporeal life support as a bridge to lung transplantation[J]. Clin Chest Med, 2011, 32(2): 245-251. DOI: 10.1016/j.ccm.2011.02.005.
    [10] 熊熙.体外膜肺氧合相关并发症及其防治[J].中国小儿急救医学, 2017, 24(2): 144-148. DOI: 10.3760/cma.j.issn.1673-4912.2017.02.013.

    XIONG X. The extracorporeal membrane oxygenation related complications and prevention[J]. Chin Ped Emerg Med, 2017, 24(2): 144-148. DOI: 10.3760/cma.j.issn.1673-4912.2017.02.013.
    [11] 胡春晓, 郑明峰, 王雁娟, 等.体外膜肺氧合在临床肺移植中的应用[J].中华器官移植杂志, 2011, 32(10): 611-613. DOI: 10.3760/cma.j.issn.0254-1785.2011.10.009.

    HU CX, ZHENG MF, WANG YJ, et al. Application of ECMO in lung transplantation[J]. Chin J Organ Transplant, 2011, 32(10): 611-613. DOI: 10.3760/cma.j.issn.0254-1785.2011.10.009.
    [12] 王兴安, 姜格宁.我国肺移植的发展现状:问题与反思[J].中华外科杂志, 2016, 54(12): 881-885. DOI: 10.3760/cma.j.issn.0529-5815.2016.12.001.

    WANG XA, JIANG GN. Current status of lung transplantation in China:problems and perspectives[J]. Chin J Surg, 2016, 54(12): 881-885. DOI: 10.3760/cma.j.issn.0529-5815. 2016.12.001.
    [13] 崔勇丽, 刘晋萍, 龙村, 等.体外膜肺氧合支持治疗中的凝血与抗凝[J].中国体外循环杂志, 2010, 8(1): 54-57. DOI: 10.3969/j.issn.1672-1403.2010.01.016.

    CUI YL, LIU JP, LONG C, et al. The coagulation and anticoagulation of extracorporeal membrane oxygenation in treatment[J]. Chin J Extra Circ, 2010, 8(1): 54-57. DOI: 10.3969/j.issn.1672-1403.2010.01.016.
    [14] DE WAELE JJ, VAN CAUWENBERGHE S, HOSTE E, et a1. The use of the activated clotting time for monitoring heparin therapy in critically ill patients[J]. Intensive Care Med, 2003, 29(2): 325-328. doi: 10.1007/s00134-002-1609-7
    [15] YOUNG G, YONEKAWA KE, NAKAGAWA P, et al. Argatroban an alternative to heparin in extracorporeal membrane oxygenation circuits[J]. Perfusion, 2004, 19(5): 283-288. doi: 10.1191/0267659104pf759oa
    [16] WHITTLESEY GC, DRUCKER DE, SALLEY SO, et al. ECMO without heparin: laboratory and clinical experience[J]. J Pediatr Surg, 1991, 26(3): 320-325. doi: 10.1016/0022-3468(91)90510-Z
    [17] 朱贤胜, 程琦, 王莎莎, 等.超声在脑-心双死亡器官捐献供肝体外膜肺氧合模式中的应用价值研究[J].器官移植, 2016, 7(2): 120-123. DOI: 10.3969/j.issn.1674-7445.2016.02.008.

    ZHU XS, CHENG Q, WANG SS, et al. Application of ultrasound in extracorporeal membrane oxygenation for the liver donation after brain-cardiac death[J]. Organ Transplant, 2016, 7(2): 120-123. DOI: 10.3969/j.issn.1674-7445.2016.02.008.
    [18] WHITTLESEY GC, DRUCKER DE, SALLEY SO, et al. ECMO without heparin: laboratory and clinical experience[J]. J Pediatr surg, 1991, 26(3): 320-324. doi: 10.1016/0022-3468(91)90510-Z
    [19] MUELLENBACH RM, KREDEL M, KUNZE E, et al. Prolonged heparin-free extracorporeal membrane oxygenation in multiple injured acute respiratory distress syndrome patients with traumatic brain injury[J].J Trauma Acute Care Surg, 2012, 72(5): 1444-1447. DOI: 10.1097/TA.0b013e31824d68e3.
  • 加载中
计量
  • 文章访问数:  135
  • HTML全文浏览量:  52
  • PDF下载量:  9
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-11-04
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2018-03-15

目录

    /

    返回文章
    返回